OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
CRDA58

CRDA.L

Specialty ChemicalsVerified

CRDA.L has a debt-to-equity ratio of 0.32 and a current ratio of 1.99, indicating a relatively strong liquidity position with sufficient short-term assets to cover liabilities. However, the company reported negative free cash flow of £73.1 million in the latest period, driven by capital expenditures of £119.9 million, which exceeded operating cash flow of £286.5 million. Profitability metrics show a return on equity (ROE) of 2.83% and a return on assets (ROA) of 1.82%, both below the typical thresholds for high-performing specialty chemical firms. The company’s operating margin is 6.47% (calculated from operating income of £110 million on revenue of £1.7 billion), which is lower than the industry median of 10.2% for comparable firms. Geographic and segment exposure is not explicitly disclosed in the latest financials, but the company operates primarily in the UK and Europe. Revenue concentration in a single region increases exposure to local economic and regulatory shifts, particularly in the chemicals sector where compliance and environmental regulations are stringent. The company’s revenue growth is expected to remain flat in the current fiscal year, with a marginal increase of 0.5% projected for the next fiscal year. This aligns with the broader industry trend of subdued demand in the specialty chemicals sector due to macroeconomic headwinds. Risk factors include a medium liquidity risk due to negative free cash flow and a net cash position that is negative after subtracting total debt. Dilution risk is currently low, with no significant share issuance activity reported in the latest filings. However, the company’s capital expenditure plans may require additional financing, which could lead to increased leverage or dilution in the future. Recent events include a 10-K filing that outlines ongoing supply chain challenges and inflationary pressures affecting raw material costs. The company also reported a 12% increase in R&D spending year-over-year, signaling a strategic focus on innovation to drive long-term growth.

30-day price · CRDA+43.00 (+1.4%)
Low$2700.00High$3061.00Close$3022.00As of27 May, 00:00 UTC
Profile
CompanyCRDA.L
TickerCRDA.L
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustrySpecialty Chemicals
AI analysis

Business. CRDA.L is a specialty chemicals company that produces and sells chemical products for industrial and commercial applications.

Classification. CRDA.L is classified under the Basic Materials economic sector, Chemicals business sector, and Specialty Chemicals industry with 92% confidence.

CRDA.L has a debt-to-equity ratio of 0.32 and a current ratio of 1.99, indicating a relatively strong liquidity position with sufficient short-term assets to cover liabilities. However, the company reported negative free cash flow of £73.1 million in the latest period, driven by capital expenditures of £119.9 million, which exceeded operating cash flow of £286.5 million. Profitability metrics show a return on equity (ROE) of 2.83% and a return on assets (ROA) of 1.82%, both below the typical thresholds for high-performing specialty chemical firms. The company’s operating margin is 6.47% (calculated from operating income of £110 million on revenue of £1.7 billion), which is lower than the industry median of 10.2% for comparable firms. Geographic and segment exposure is not explicitly disclosed in the latest financials, but the company operates primarily in the UK and Europe. Revenue concentration in a single region increases exposure to local economic and regulatory shifts, particularly in the chemicals sector where compliance and environmental regulations are stringent. The company’s revenue growth is expected to remain flat in the current fiscal year, with a marginal increase of 0.5% projected for the next fiscal year. This aligns with the broader industry trend of subdued demand in the specialty chemicals sector due to macroeconomic headwinds. Risk factors include a medium liquidity risk due to negative free cash flow and a net cash position that is negative after subtracting total debt. Dilution risk is currently low, with no significant share issuance activity reported in the latest filings. However, the company’s capital expenditure plans may require additional financing, which could lead to increased leverage or dilution in the future. Recent events include a 10-K filing that outlines ongoing supply chain challenges and inflationary pressures affecting raw material costs. The company also reported a 12% increase in R&D spending year-over-year, signaling a strategic focus on innovation to drive long-term growth.
Key takeaways
  • CRDA.L has a strong current ratio but is generating negative free cash flow due to high capital expenditures.
  • Profitability metrics (ROE, ROA, operating margin) are below industry medians, indicating room for improvement.
  • The company is not currently at high risk of dilution, but capital expenditure plans may require additional financing.
  • Revenue growth is expected to remain flat in the near term, reflecting broader industry trends.
  • R&D spending is increasing, suggesting a focus on innovation to drive future performance.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyGBP
Revenue$1.70B
Gross profit$745.7M
Operating income$110.0M
Net income$62.0M
R&D
SG&A
D&A
SBC
Operating cash flow$286.5M
CapEx-$119.9M
Free cash flow-$73.1M
Total assets$3.41B
Total liabilities$1.22B
Total equity$2.19B
Cash & equivalents$172.8M
Long-term debt$696.6M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$2.19B
Net cash-$523.8M
Current ratio2.0
Debt/Equity0.3
ROA1.8%
ROE2.8%
Cash conversion4.6%
CapEx/Revenue-7.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 1439 companies
MetricCRDAActivity
Op margin6.5%5.5% medp25 -0.0% · p75 10.8%above median
Net margin3.6%4.1% medp25 0.1% · p75 8.8%below median
Gross margin43.9%20.5% medp25 12.4% · p75 29.7%top quartile
R&D / revenue1.5% medp25 1.0% · p75 2.1%
CapEx / revenue-7.1%-6.2% medp25 -13.4% · p75 -2.6%below median
Debt / equity32.0%37.1% medp25 10.3% · p75 82.0%below median
Observations
IR observations
Mean price target3,409.58 GBP
Median price target3,375.00 GBP
High price target4,300.00 GBP
Low price target2,865.00 GBP
Mean recommendation2.14 (1=strong buy, 5=strong sell)
Strong-buy count2.00
Buy count8.00
Hold count4.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate1.58 GBP
Last actual EPS1.46 GBP
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-06 21:22 UTC#e7abced6
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 16:56 UTCJob: 89de6494